Future Oncology

Article	Citations
First-Line Pembrolizumab/Placebo Plus Trastuzumab and Chemotherapy in Her2-Positive Advanced Gastric Cancer: KEYNOTE-811	115
Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA	87
The Abscopal Effect of Radiation Therapy	74
Immune-Based Combinations for Advanced Hepatocellular Carcinoma: Shaping the Direction of First-Line Therapy	73
KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma	72
An Insight Into the Cancer Stem Cell Survival Pathways Involved in Chemoresistance in Triple-Negative Breast Cancer	72
MAHOGANY: Margetuximab Combination in HER2+ Unresectable/metastatic Gastric/gastroesophageal Junction Adenocarcinoma	70
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer	56
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer	53
Systemic Therapy of Advanced Hepatocellular Carcinoma	52
Immune-Related Adverse Events with PD-1 Versus PD-L1 Inhibitors: A Meta-Analysis of 8730 Patients from Clinical Trials	49
The LEAP Program: Lenvatinib Plus Pembrolizumab for the Treatment of Advanced Solid Tumors	47
Benefits and Limitations of Real-World Evidence: Lessons from EGFR Mutation-Positive Non-Small-Cell Lung Cancer	45
CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies	44
Organ Tropism in Solid Tumor Metastasis: An Updated Review	43
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma	41
Atezolizumab and Bevacizumab for Hepatocellular Carcinoma: Mechanism, Pharmacokinetics and Future Treatment Strategies	39
Cancer and COVID-19: Analysis of Patient Outcomes	37
Perceptions of the COVID-19 vaccine Among Patients With Cancer: A Single-Institution Survey	36
KEYNOTE-859: a Phase III Study of Pembrolizumab Plus Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma	36
Oncolytic viruses: challenges and considerations in an evolving clinical landscape	35
Dostarlimab in the Treatment of Recurrent or Primary Advanced Endometrial Cancer	34
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design	32
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial	32
GALNT14 Regulates Ferroptosis and Apoptosis of Ovarian Cancer Through the EGFR/mTOR Pathway	31

Phase III Study of Selpercatinib Versus Chemotherapy ± pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer	31
INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in MET -Amplified NSCLC and First-Line Osimertinib Resistance	31
Precision Oncology: a Clinical and Patient Perspective	31
MOMENTUM: Momelotinib Vs Danazol in Patients with Myelofibrosis Previously Treated with JAKi Who Are Symptomatic and Anemic	31
A Ferroptosis-Related Gene Signature Predicts Overall Survival in Patients with Lung Adenocarcinoma	30
Immunogenicity and Safety of the Coronavac Vaccine in Patients with Cancer Receiving Active Systemic Therapy	30
Survival and Complications After Neoadjuvant Chemotherapy or Chemoradiotherapy for Esophageal Cancer: A Meta-Analysis	30
Oral Health-Related Quality of Life in Oral Cancer Patients: Systematic Review and Meta-Analysis	29
Trifluridine/Tipiracil Plus Bevacizumab for Third-Line Management of Metastatic Colorectal Cancer: SUNLIGHT Study Design	29
Understanding Patient Factors to Increase Uptake of Cancer Screening: a Review	29
Current Trends in the Treatment of HR+/HER2+ Breast Cancer	29
Dna Damage Response Alterations in Gastric Cancer: Knocking down a New Wall	28
Idecabtagene Vicleucel (ide-cel) CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma	28
Race and Ethnicity Representation in Clinical Trials: Findings from a Literature Review of Phase I Oncology Trials	28
KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer	28
Canakinumab with and Without Pembrolizumab in Patients with Resectable Non-Small-Cell Lung Cancer: CANOPY-N Study Design	27
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?	26
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer	26
Enhanced Metastatic Risk Assessment in Cutaneous Squamous Cell Carcinoma with the 40-Gene Expression Profile Test	25
Perioperative Pembrolizumab Therapy in Muscle-Invasive Bladder Cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303	25
How We Treat Merkel Cell Carcinoma: Within and Beyond Current Guidelines	25
Revisiting the Role of TRAIL/TRAIL-R in Cancer Biology and Therapy	25
Surgery for pancreatic cancer: current controversies and challenges	25
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma	25
KEYNOTE-641: A Phase III Study of Pembrolizumab Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer	24
Ezh2 Inhibition by Tazemetostat: Mechanisms of Action, Safety and Efficacy in Relapsed/refractory Follicular Lymphoma	24
Efficacy and Safety Profile of COVID-19 Vaccine in Cancer Patients: A Prospective, Multicenter Cohort Study	24
A Real-World US Study of Recurrence Risks using Combined Clinicopathological Features in HR-Positive, HER2-Negative Early Breast Cancer	23
Indications for and Contraindications of Immune Checkpoint Inhibitors in Cancer Patients with COVID-19 Vaccination	23
Belantamab Mafodotin in Combination with Novel Agents in Relapsed/refractory Multiple Myeloma: DREAMM-5 Study Design	23
Quality of Life Assessment in Renal Cell Carcinoma Phase II and III Clinical Trials Published between 2010 and 2020: a Systematic Review	23
RaPiDS (GOG-3028): Randomized Phase II Study of Balstilimab Alone or in Combination with Zalifrelimab in Cervical Cancer	22
Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer	22
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas	22
Real-World Treatment Patterns, Healthcare Use and Costs in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Patients in the USA	22
SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia	22
Clinical Activity and Safety of the Anti-PD-1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced dMMR Endometrial Cancer	21
Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis	21
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatment	21
Tazemetostat for Advanced Epithelioid Sarcoma: Current Status and Future Perspectives	21
Current and Potential Biomarkers in Gastric Cancer: a Critical Review of the Literature	20
Hypersensitivity Reactions to Asparaginase Therapy in Acute Lymphoblastic Leukemia: Immunology and Clinical Consequences	20
Role of Nutritional Care and General Guidance for Patients with Advanced or Metastatic Gastric Cancer	20
Circulating Serum Exosomal miR-92a-3p as a Novel Biomarker for Early Diagnosis of Gastric Cancer	19
Prognostic Significance of Hemoglobin-To-Red Cell Distribution Width Ratio in Patients with Metastatic Renal Cancer	19
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer	19
Atezolizumab and Bevacizumab with Transarterial Chemoembolization in Hepatocellular Carcinoma: The DEMAND Trial Protocol	19
Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid Cancer	18
Oncolytic Virotherapy as Promising Immunotherapy Against Cancer: Mechanisms of Resistance to Oncolytic Viruses	18
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Metastatic Breast Cancer: Plain Language Summary of the DESTINY-Breast01 Study	18

Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design	18
Tremelimumab and Durvalumab in the Treatment of Unresectable, Advanced Hepatocellular Carcinoma	18
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need	18
Implementing Multidisciplinary Tumor Boards in Oncology: a Narrative Review	18
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	18
Solitary Fibrous Tumor: Molecular Hallmarks and Treatment for a Rare Sarcoma	17
Real-World Homologous Recombination Repair Mutation Testing in Metastatic Castration-Resistant Prostate Cancer in the USA, Europe and Japan	17
Axicabtagene Ciloleucel and Brexucabtagene Autoleucel in Relapsed and Refractory Diffuse Large B-Cell and Mantle Cell Lymphomas	17
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery	17
Prognostic Implications of Depression and Inflammation in Patients With Metastatic Lung Cancer	16
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review	16
Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations	16
A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas	16
Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia	16
Multimodal Analysis of ctDNA Methylation and Fragmentomic Profiles Enhances Detection of Nonmetastatic Colorectal Cancer	16
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon	16
Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer	16
Expression Profiles and Prognostic Roles of m6A Writers, Erasers and Readers in Gastric Cancer	16
Analysis of Risk Factors for Immune-Related Adverse Events in Various Solid Tumors Using Real-World Data	16
Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer	15
Molecular Tests and Target Therapies in Oncology: Recommendations from the Italian Workshop	15
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design	15
Serum Exosomal miR-377-3p and miR-381-3p as Diagnostic Biomarkers in Colorectal Cancer	15
Preferences of Adults with Cancer for Systemic Cancer Treatment: Do Preferences Differ Based on Age?	15
CaboPoint: A Phase II Study of Cabozantinib as Second-Line Treatment in Patients with Metastatic Renal Cell Carcinoma	15
Defining Treatment Regimens and Lines of Therapy Using Real-World Data in Oncology	15
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy	15
Real-World Effectiveness of Lenvatinib Monotherapy Among Unresectable Hepatocellular Carcinoma Patients in the USA	15
Discovering the First US FDA-Approved Computer-Aided Polyp Detection System	15
Encorafenib Plus Binimetinib in Patients with BRAF V600 -Mutant Non-Small Cell Lung Cancer: Phase II PHAROS Study Design	15
Patient Satisfaction with Telemedicine for Prechemotherapy Evaluation During the COVID-19 Pandemic	15
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer	15
Role of PSMA PET/CT Imaging in the Diagnosis, Staging and Restaging of Prostate Cancer	15
Pattern of breast cancer presentation during the COVID-19 pandemic: results from a cohort study in the UK	15
2022 cancer statistics: Focus on lung cancer	15
Treatment Patterns in Patients with Metastatic Non-Small-Cell Lung Cancer in the Era of Immunotherapy	15
A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax Plus Docetaxel in Patients with Advanced Solid Tumors	15
Metastatic Lymph Node Ratio as a better Prognostic Tool than The TNM System in Colorectal Cancer	14
Circulating DNA Methylation Profile Improves the Accuracy of Serum Biomarkers for the Detection Of Nonmetastatic Hepatocellular Carcinoma	14
Targeting FGFR3 Alterations with Adjuvant Infigratinib in Invasive Urothelial Carcinoma: the Phase III PROOF 302 Trial	14
Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- IDH1 Cholangiocarcinoma	14
How we Treat HR-Positive, HER2-Negative Early Breast Cancer	14
A Call to Action: Antiracist Patient Engagement in Adolescent and Young Adult Oncology Research and Advocacy	14
Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index	14
Real-World Effectiveness Outcomes in Patients Diagnosed with Metastatic Triple-Negative Breast Cancer	14
Soluble PD-L1 as a Predictive Biomarker in Lung Cancer: A Systematic Review and Meta-Analysis	14
FRESCO-2: A Global Phase III Study Investigating the Efficacy and Safety of Fruquintinib in Metastatic Colorectal Cancer	14
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer	14
Real-World Treatment of Patients with Palbociclib for HR+/HER2-Advanced/Metastatic Breast Cancer: The Europe IRIS Study	14
Venetoclax-Based Combinations for the Treatment of Newly Diagnosed Acute Myeloid Leukemia	13
Lurbinectedin in the Treatment of Relapsed Small Cell Lung Cancer	13
Ixazomib-Lenalidomide-Dexamethasone in Routine Clinical Practice: Effectiveness in Relapsed/refractory Multiple Myeloma	13
Development and Validation of Nomograms for Epithelial Ovarian Cancer: a SEER Population-Based, Real-World Study	13
Role of Cedazuridine/Decitabine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia	13
Patient Engagement in Cancer Research from the Patient’s Perspective	13
Diagnostic and Economic Value of Biomarker Testing for Targetable Mutations in Non-Small-Cell Lung Cancer: a Literature Review	13
Plasma exosomal miR-1260a, miR-7977 and miR-192-5p as diagnostic biomarkers in epithelial ovarian cancer	13
Nanotechnology-Based Platforms to Improve Immune Checkpoint Blockade Efficacy in Cancer Therapy	13
Real-World Clinical Outcomes with First-Line Avelumab in Locally Advanced/metastatic Merkel Cell Carcinoma in the USA: SPEAR-Merkel	13
Financial Toxicity and its Impact on Health Outcomes and Caregiver Burden Among Adult Cancer Survivors in the USA	13
Turalio Risk Evaluation and Mitigation Strategy for Treatment of Tenosynovial Giant Cell Tumor: Framework And Experience	13
Use of Real-World Evidence for Oncology Clinical Decision Making in Emerging Economies	13
Predicting Occult Lymph Node Metastasis by Nomogram in Patients with Lung Adenocarcinoma ≤2 cm	13
Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors	13
Apalutamide, Darolutamide and Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: A Meta-Analysis	13
IL-10 in cancer: an essential thermostatic regulator between homeostatic immunity and inflammation – a comprehensive review	12
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC	12
Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma	12
Pd-L1 Testing Based on The SP142 Antibody in Metastatic Triple-Negative Breast Cancer: Summary of an Expert Round-Table Discussion	12
Overcoming Immunosuppression and Pro-Tumor Inflammation in Lung Cancer with Combined IL-1β and PD-1 Inhibition	12
Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies	12
The role of Globo H and SSEA-4 in the Development and Progression of Cancer, and their Potential as Therapeutic Targets	12
Impact of Corona-Phobia on Attitudes and Acceptance Towards COVID-19 Vaccine Among Cancer Patients: a Single-Center Study	12
Brigatinib Versus Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3)	12
EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)	12
Telehealth Amid the COVID-19 Pandemic: Perception Among Asian, Native Hawaiian and Pacific Islander Cancer Patients	12
Upregulated Expression of MTFR2 as a Novel Biomarker Predicts Poor Prognosis in Hepatocellular Carcinoma by Bioinformatics Analysis	12
Patient Preferences for Advanced Hepatocellular Carcinoma Treatment: A Multicountry Stated Preference Study	12
LIBRETTO-432, a Phase III Study of Adjuvant Selpercatinib or Placebo in Stage IB-IIIA RET Fusion-Positive Non-Small-Cell Lung Cancer	12
PALVEN: Phase Ib Trial of Palbociclib, Letrozole and Venetoclax in Estrogen Receptor- and BCL2-Positive Advanced Breast Cancer	12

Single Agent VS-6766 or VS-6766 Plus Defactinib in KRAS -Mutant Non-Small-Cell Lung Cancer: The RAMP-202 Phase II Trial	12
BOREAS: A Global, Phase III Study of the MDM2 Inhibitor Navtemadlin (KRT-232) in Relapsed/Refractory Myelofibrosis	12
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2	12
Pragmatic Patient Engagement in Designing Pragmatic Oncology Clinical Trials	12
Efficacy of PD-1/L1 Inhibitors in Brain Metastases of Non-Small-Cell Lung Cancer: Pooled Analysis from Seven Randomized Controlled Trials	11
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)	11
KEYNOTE-991: Pembrolizumab Plus Enzalutamide and Androgen Deprivation for Metastatic Hormone-Sensitive Prostate Cancer	11
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review	11
Patient Preferences for Breast Cancer Treatments: A Discrete Choice Experiment in France, Ireland, Poland and Spain	11
Extraskeletal Osteosarcomas: Current Update	11
ALTA-2: Phase II Study of Brigatinib in Patients with ALK-Positive, Advanced Non-Small-Cell Lung Cancer Who Progressed on Alectinib or Ceritinib	11
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast	11
IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute	11
Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges	11
Momelotinib for the treatment of myelofibrosis with anemia	11
Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer	11
Treatment Patterns and Clinical Outcomes Of palbociclib-Based Therapy Received in US Community Oncology Practices	11
Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer	11
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma	11
Telemedicine Health Disparities in Oncology Care	10
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma	10
Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis	10
Prognostic significance of baseline neutrophil–lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data	10
Incidence, Predictors and 6-Month Overall Outcome of Acute Kidney Injury in Chinese Patients Receiving PD-1 Inhibitors	10
TRIM58 is a Prognostic Biomarker Remodeling the Tumor Microenvironment in KRAS -Driven Lung Adenocarcinoma	10
Medication Adherence Among Patients with Advanced Prostate Cancer Using Oral Therapies	10
KEYNOTE – D36: Personalized Immunotherapy with a Neoepitope Vaccine, EVX-01 and Pembrolizumab in Advanced Melanoma	10
VGH-TAYLOR: Comprehensive Precision Medicine Study Protocol on the Heterogeneity of Taiwanese Breast Cancer Patients	10
Bladder cancer diagnosis with a four-miRNA panel in serum	10
Bidirectional Deep Neural Networks to Integrate RNA and DNA Data for Predicting Outcome for Patients with Hepatocellular Carcinoma	10
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer	10
Proximal Versus Total Gastrectomy for Proximal Gastric Cancer: a Surveillance, Epidemiology, and End Results Program Database Analysis	10
Progress and Prospects of Immune Checkpoint Inhibitors in Advanced Gastric Cancer	10
Plasma SNORD83A as a Potential Biomarker for Early Diagnosis Of Non-Small-Cell Lung Cancer	10
Real-World Characteristics and Outcomes of Advanced Non-Small-Cell Lung Cancer Patients with EGFR Exon 19 Deletions or Exon 21 Mutations	9
Is the CyberKnife ® radiosurgery system effective and safe for patients? An umbrella review of the evidence	9
MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	9
Single-Dose Netupitant/Palonosetron Versus 3-day Aprepitant for Preventing Chemotherapy-Induced Nausea and Vomiting: A Pooled Analysis	9
A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer	9
Epidemiologic Trends and Prognostic Risk Factors of Patients with Pancreatic Neuroendocrine Neoplasms in the US: an Updated Population-Based Study	9
MiR-133b Inhibits Colorectal Cancer Metastasis via lncRNA-LUCAT1	9
Identification of a lncRNA Prognostic Signature-Related to Stem Cell Index and its Significance in Colorectal Cancer	9
Trabectedin as Second-Line Treatment in Advanced Soft Tissue Sarcoma: Quality of Life and Safety Outcomes	9
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors	9
CDK4/6 Inhibitors: Mechanisms of Resistance and Potential Biomarkers of Responsiveness in Breast Cancer	9
Indirect Treatment Comparisons of Avapritinib Versus Midostaurin for Patients with Advanced Systemic Mastocytosis	9
Systemic Immune-Inflammation Index Changes Predict Outcome in Stage III Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy	9
Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data	9
The Right Immune-Modulation at the Right Time: Thymosin α1 for Prevention of Severe COVID-19 in Cancer Patients	9
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	9
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for hepatocellular carcinoma: a meta-analysis	9
Bugs as Drugs: Neglected but a Promising Future Therapeutic Strategy in Cancer	8
Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study	8
Relationship Between Antidepressive Agents and Incidence Risk of Breast Cancer: Systematic Review and Meta-Analysis	8
Predicting Future Cancer Burden in the United States By Artificial Neural Networks	8
Lorlatinib as a treatment for ALK-positive lung cancer	8
Current State and Comparison of the Clinical Development of Bevacizumab, Rituximab and Trastuzumab Biosimilars	8
TRUST-II: a global phase II study of taletrectinib in ROS1 -positive non-small-cell lung cancer and other solid tumors	8
To Betray or to Fight? The Dual Identity of the Mitochondria in Cancer	8
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia	8
Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study	8
Navigating the High Costs of Cancer Care: Opportunities for Patient Engagement	8
Pharmacotherapy for Liposarcoma: Current and Emerging Synthetic Treatments	8
BRUIN MCL-321: Phase III Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in BTK Inhibitor Naive Mantle Cell Lymphoma	8
Targeting LIN28: A New Hope in Prostate Cancer Theranostics	8
Efficacy and Safety of Recombinant Human Endostatin During Peri-Radiotherapy Period in Advanced Non-Small-Cell Lung Cancer	8
Immune-Related Genes LAMA2 and IL1R1 Correlate with Tumor Sites and Predict Poor Survival in Pancreatic Adenocarcinoma	8
Real-World Association of HER2/ ERBB2 Concordance with Trastuzumab Clinical Benefit in Advanced Esophagogastric Cancer	8
Genetic Variants in NPAS2 Gene and Clinical Outcomes of Resectable Non-Small-Cell Lung Cancer	8
LncRNA PCAT7 Promotes the Malignant Progression of Breast Cancer by Regulating ErbB/PI3K/Akt Pathway	8
Oral Submucous Fibrosis and Heterogeneity in Outcome Measures: A Critical Viewpoint	8
BRCA1/2 Signaling and Homologous Recombination Deficiency in Breast and Ovarian Cancer	8
Infectious complications and immunotherapy: old pitfalls and new horizons	8
The Prognostic Impacts of PABPC1 Expression on Gastric Cancer Patients	8
Surgery in Soft Tissue Sarcoma: the Thin Line between a Surgical or more Conservative Approach	8
COVID-19 and breast cancer: may the microbiome be the issue?	8
Italian Results of the PRECONNECT Study: Safety and Efficacy of Trifluridine/tipiracil in Metastatic Colorectal Cancer	8
Diagnostic and Prognostic Value of HOXC Family Members in Gastric Cancer	8
Trends in Real-World Biomarker Testing and Overall Survival in US Patients with Advanced Non-Small-Cell Lung Cancer	8
High PD-L1 Expression on Immune Cells, But not on Tumor Cells, is a Favorable Prognostic Factor in Urothelial Carcinoma	8
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer	8
The treatment of advanced pulmonary sarcomatoid carcinoma	7
Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?	7
PIVOT-12: a Phase III Study of Adjuvant Bempegaldesleukin Plus Nivolumab in Resected Stage III/IV Melanoma at High Risk for Recurrence	7
Factors for Incidence Risk and Prognosis in Non-Small-Cell Lung Cancer Patients with Synchronous Brain Metastasis: A Population-Based Study	7
Eribulin in Brain Metastases of Breast Cancer: Outcomes of the EBRAIM Prospective Observational Trial	7
Biosimilars in an Era of Rising Oncology Treatment Options	7
Increasing Access to Quality Anticancer Medicines in Low- and Middle-Income Countries: The Experience of Uganda	7
Real-World Use and Acceptance of Biosimilar Monoclonal Antibodies of Rituximab in Oncology Practice in the USA	7
Prognostic Value of Platelet Distribution Width and Mean Platelet Volume in Patients with Laryngeal Cancer	7
Nat1 is a Critical Prognostic Biomarker and Inhibits Proliferation of Colorectal Cancer Through Modulation of PI3K/Akt/mTOR	7
Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond)	7
Parp Inhibitor Treatment of Advanced Breast Cancer Beyond the BRCA -Mutated Type: A Meta-Analysis	7
Truscreen Detection of Cervical Tissues for High-Risk Human Papillomavirus-Infected Women During the COVID-19 Pandemic	7
First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population	7